Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

Original Article

M.R. Mirza, D.M. Chase, B.M. Slomovitz, R.d. Christensen, Z. Novák, D. Black, L. Gilbert, S. Sharma, G. Valabrega, L.M. Landrum, L.C. Hanker, A. Stuckey, I. Boere, M.A. Gold, A. Auranen, B. Pothuri, D. Cibula, C. McCourt, F. Raspagliesi, M.S. Shahin, S.E. Gill, B.J. Monk, J. Buscema, T.J. Herzog, L.J. Copeland, M. Tian, Z. He, S. Stevens, E. Zografos, R.L. Coleman, and M.A. Powell

N Engl J Med 2023;388:2145-2158

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Course opens: 
06/07/2023
Course expires: 
06/08/2025

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation